Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
This study has been completed.
Study NCT00006340 Information provided by National Cancer Institute (NCI)
First Received: October 4, 2000 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Lymphoma
Precancerous/Nonmalignant Condition
Small Intestine Cancer
Additional conditions recognized in this trial
Duodenal Neoplasms
Ileal Neoplasms
Intestinal Neoplasms
Jejunal Neoplasms
Lymphoma, Large-Cell, Immunoblastic
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Precancerous Conditions
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Duodenal Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Ileal Diseases
Immune System Diseases
Immunoproliferative Disorders
Intestinal Diseases
Jejunal Diseases
Lymphatic Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Interventions listed in this trial
arginine butyrate
ganciclovir
More general drug interventions related to this trial
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Boston Medical Center
Back to top of Main Content
